On November 9, 2026, California voters approved Proposition 38, allowing the state to issue $8.4 billion in bonds for immunology and immunotherapy research. The goal is to find cures and prevent chronic diseases.
The measure, confirmed by the Associated Press on Monday evening, mandates that at least $4.2 billion focus on research related to cancer, heart disease, and Alzheimer’s disease. Additionally, the state will partner with a selected immunology and immunotherapy research institute, chosen by the California Department of Public Health. This institute will receive half of the bond revenue.
Opponents expressed concerns that this initiative could burden taxpayers with long-term debt and noted that current grant requirements are so specific that only one institute, the California Institute for Immunology and Immunotherapy, qualifies for the funding. Gary K. Michelson, a co-founder of the institute, authored the proposition and was its largest financial supporter, contributing $45 million per state data.
Funds not designated for the institute will be used for competitive research grants. These grants aim to advance immunology and immunotherapy and will be distributed by a council of representatives from University of California campuses and other universities and nonprofit research institutions.
Supporters of Proposition 38 celebrated its passage, emphasizing the positive impact on research progress amid federal funding cuts. In a press release, they noted that the measure addresses disruptions in clinical trials and setbacks in medical discovery. Chris Tarver, president of the American Nurses Association\California, stated, “This victory belongs to the patients and families who have spent years fighting devastating diseases and waiting for the next medical breakthrough.”
The Legislative Analyst’s Office estimates that Californians will incur an annual cost of $500 to $600 million to repay the bond over 20 years. Some costs may be offset if funded research results in commercially viable treatments, though this outcome remains uncertain.
